Nitrous Oxide Emissions: Lonza Will Implement Innovative Solution Before End of 2021

Visp, 10 December 2020 – Lonza discovered the nitrous oxide emissions during a regular measurement at the site in Visp, CH. As soon as the findings had been confirmed by an external body, work began on a technical solution to reduce the emissions, developed in close cooperation with the Federal Office for the Environment (FOEN). Through the installation of a catalyzer, Lonza will be able to reduce nitrous oxide emissions in niacin production by at least 98%. The catalyzer represents a technical fix that keeps nitrous oxide emissions to a minimum, despite there being no regulatory limits for this. The cost of implementation is approximately CHF 12 million, which is being pre-financed by Lonza. For Lonza, the development of a technical solutions to reduce the emissions has always been the driving force, irrespective of the cost.

The planning application for the catalyzer was submitted in November 2019, while initial preparatory work was underway and material orders were being placed. At the end of January 2020, Lonza received the building permit from the canton and the municipality, and immediately began the catalyzer project. The system covers a total area of 95 m2 and is 18 m in height. Due to delays at the catalyzer supplier as a result of the coronavirus pandemic, the commissioning originally planned for the end of 2021 was likely to be subject to delays. These supply issues have now been resolved and Lonza has been able to expedite the delivery. Based on the latest reports, Lonza now expects the catalyzer system to be operational before the end of 2021, as originally planned, provided delivery goes according to plan and there are no further coronavirus-related delays.

Lonza is a company with 123 years of industrial history in the canton of Valais. In recent years we have actively tackled a number of legacy issues and successfully implemented solutions. One example of this is the mercury clean-up in the Rhone Valley, which has already been put into action on around 70% of the affected residential plots of land.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.


Mathias Forny
Deputy Head of Communications and Site Marketing
Tel. 41 79 508 78 22
[email protected]

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.